Regulus Therapeutics Inc.
RGLS
Ранг среди акций
#17332
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Цена акции
$8.16
Последняя синхронизация: 2025-06-26
Рыночная капитализация
$234.57M
Изменение (1 день)
0.00%
Изменение (1 год)
-56.96%
Страна
US
Торговля Regulus Therapeutics Inc. (RGLS)
Категория
Healthcare
Количество находящихся в обращении акций Regulus Therapeutics Inc. (RGLS)
Количество акций в обращении на March 2024: 150.47M
Согласно последним финансовым отчетам и цене акций Regulus Therapeutics Inc., текущее количество акций в обращении составляет 150.47M. На конец December 2022 у компании было 136.62M акций в обращении. Количество акций в обращении обычно зависит от сплитов и обратного выкупа акций.
История количества акций в обращении Regulus Therapeutics Inc. (RGLS) с 2002 по 2026
Акции в обращении на конец каждого года
| Год | Акции в обращении | Изменить |
|---|---|---|
| 2026 (TTM) | 150.47M | 9.64% |
| 2023 | 137.24M | 0.45% |
| 2022 | 136.62M | 2.26% |
| 2021 | 133.60M | 1.37% |
| 2020 | 131.79M | 4.27% |
| 2019 | 126.40M | 0.83% |
| 2018 | 125.36M | 8.26% |
| 2017 | 115.79M | 9.47% |
| 2016 | 105.77M | 1.15% |
| 2015 | 104.57M | 4.13% |
| 2014 | 100.42M | 2.18% |
| 2013 | 98.28M | 3.83% |
| 2012 | 94.65M | -74.15% |
| 2011 | 366.20M | 1.02% |
| 2010 | 362.50M | 0.85% |
| 2009 | 359.44M | 1.12% |
| 2008 | 355.47M | 4.07% |
| 2007 | 341.56M | 11.55% |
| 2006 | 306.19M | 14.34% |
| 2005 | 267.79M | 8.72% |
| 2004 | 246.31M | 18.44% |
| 2003 | 207.96M | 12.86% |
| 2002 | 184.26M | 0.00% |
Акции в обращении у аналогичных компаний или конкурентов
| Компания | Акции в обращении | Разница | Страна |
|---|---|---|---|
| 253.90M | 68.74% |
US
|
|
| 396.00M | 163.17% |
US
|
|
| 478.91M | 218.27% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -58.67% |
NL
|
